EXEL exelixis.com: Enterprise Value to EBITDA Ratio

Corporate company logo of exelixis.com (EXEL)

The historical EV/EBITDA chart for Exelixis, Inc. (EXEL) demonstrates business value dynamics supported by a streamlined distribution of targeted drugs through a network of reliable carriers. The biotech's current success depends on patent protection and the approval of insurance reimbursements. 15.95 is the current value of the metric, capturing the scaling phase of the core portfolio and the investment of funds into new medical developments.

EXEL (Exelixis Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/11/2026

Comprehensive metric breakdowns and analytics for exelixis.com (EXEL)

- stock price and consensus target price:
Stock Quotes Exelixis Corp|EXEL - Average Forecast Price
- company stock capitalization data:
Market Valuation Exelixis Inc.|EXEL - Value Adjusted for Debt and Cash
- business book valuation details:
Accounting Value per Share Exelixis|EXEL - Total Net Assets|Market Capitalization to Book Value Ratio exelixis.com|EXEL - Company Total Assets
- debt and solvency information:
Debt to Equity Exelixis, Inc.|EXEL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Exelixis|EXEL - Company Total Indebtedness|Debts to Book Capitalization Exelixis Inc.|EXEL - Long-Term Debt|Company Current Liabilities Exelixis|Quick Ratio exelixis.com
- net income and valuation multiples indicators:
EXEL - Company Net Income|Projected Future Earnings Exelixis, Inc.|EXEL - Price to Earnings Multiple|Projected Price to Earnings Exelixis, Inc.|EXEL - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Exelixis Inc.|EXEL - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Exelixis|EXEL - Earnings per share for the trailing year|Quarterly EPS earnings growth exelixis.com|EXEL - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Exelixis, Inc.
Basic company analysis:Exelixis Corp EXEL
Original product of exelixis.com

EV/EBITDA measures the total enterprise value relative to earnings before depreciation, taxes, and interest, revealing the actual premium paid for an asset. For Exelixis, Inc. (EXEL), this calculation confirms the effective monetization of Cabometyx through stable cash flow. By analyzing the EV/EBITDA multiple chart, an investor can detect market overheating in a timely manner. Low indicator values underscore the fundamental resilience of Exelixis, Inc. (EXEL) even in the presence of patent risks.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Nuvalent Therapeutics (NUVL) - Company Value to EBITDA|KYMR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation IDYA (ideayabio.com)|ELVN (Enliven Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|ORIC: Enterprise Value to Operating Income Before Depreciation Ratio|RLAY (Relay Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Nurix Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tyra Biosciences, Inc. (TYRA)|VSTM (verastem.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GLUE (Monte Rosa Therapeutics, Inc.)|Enterprise Value to EBITDA Multiple Cullinan Oncology|Immuneering Inc. - EV/EBITDA Multiple|Company Value to EBITDA C4 Therapeutics Corp|BDTX (Black Diamond) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple